Availability of data and material Not applicable
The primary composite endpoint (cardiovascular death or worsening heart failure) was reached in 9,9% of the tirzepatide arm versus 15,3% of the placebo arm (HR 0,62, p=0,026)
There is also a trial specifically testing whether retatrutide prevents heart attacks and strokes (TRIUMPH-3, 1,800 people), and a head-to-head trial comparing retatrutide directly against tirzepatide (the active ingredient in Zepbound) under identical conditions (NCT06662383, 800 patients)
Blood vessels experience years of silent damage
These include: Nausea (the most common complaint, particularly during dose escalation) Vomiting Diarrhoea Constipation Decreased appetite These effects are generally dose-dependent and tend to be most pronounced during the initial weeks of treatment or following a dose increase
Vaginal health changes during semaglutide treatment are real, but they are not caused by the medication directly